Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes

Katrin Schimke; Timothy M E Davis

Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes

Curr Opin Investig Drugs. 2007 Apr;8(4):338-44.

Authors

Katrin Schimke¹, Timothy M E Davis

Affiliation

¹ University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, WA 6959, Australia. kschimke@meddent.uwa.edu.au

PMID: 17458185

Abstract

Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.

Publication types

Review

MeSH terms

Administration, Oral
Animals
Clinical Trials, Phase III as Topic
Diabetes Mellitus, Type 2 / drug therapy*
Drug Evaluation / methods*
Drug Evaluation, Preclinical / methods
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / chemistry
Hypoglycemic Agents / therapeutic use*
Molecular Structure
Thiazolidinediones / administration & dosage
Thiazolidinediones / chemistry
Thiazolidinediones / therapeutic use*

Substances

Hypoglycemic Agents
Thiazolidinediones
rivoglitazone